| Schedule of computation of basic and diluted net loss per share |
| | | | | | | | | Three months ended | | | May 31, | | | 2021 | | 2020 | Net loss | | $ | (48,707) | | $ | (13,960) | Weighted-average shares used in computing net loss per share | | | 58,261,233 | | | 7,524,016 | Net loss per share attributable to common stockholders, basic and diluted | | $ | (0.84) | | $ | (1.86) |
|
| Schedule of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders |
| | | | | | | Three months ended | | | May 31, | | | 2021 | | 2020 | Stock options | | 8,448,011 | | 8,003,098 | Unvested restricted stock units | | 501,952 | | — | Shares issued to 2nd.MD employees and subject to vesting | | 608,332 | | — | Contingent shares in connection with 2nd.MD acquisition | | 1,889,441 | | — | Convertible Senior Notes | | 5,700,297 | | — | Common stock warrants | | — | | 157,882 | Total | | 17,148,033 | | 8,160,980 |
|